Background {#Sec1}
==========

MetS is a cluster of metabolic risk factors that are associated with an increased risk of metabolic related diseases such as cardiovascular diseases (CVD) and type 2 diabetes (T2D) \[[@CR1]--[@CR3]\]. In a meta-analysis study, MetS was shown to cause a twofold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality \[[@CR1]\]. Central obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose and insulin resistance are the most pivotal components of MetS \[[@CR4]--[@CR7]\]. MetS is also characterized by a chronic low grade inflammation state which can explain the increased CVD and T2D risk \[[@CR8]\]. HsCRP is a proinflammatory protein that is produced by the liver in response to cytokine production due to acute inflammation. HsCRP is a marker of low grade inflammation which was shown in many studies to be higher in subjects with MetS. It was also shown that increased level of HsCRP is associated with increased risk of CVD and T2D \[[@CR9]--[@CR11]\]. Furthermore, it was shown that adding HsCRP to the definition of MetS will increase its predictive power of CVD and T2D \[[@CR9]--[@CR12]\].

ANGPTL8 is another liver produced protein that has been recently given increased attention due to its role in lipid metabolism and insulin resistance \[[@CR13]--[@CR15]\]. ANGPTL8 showed high level of expression in white, brown adipose tissues as well as the liver \[[@CR14], [@CR15]\]. It was suggested that ANGPTL8 is an atypical ANGTPL protein which closely interacts and regulates ANGTPL3 affecting levels of TG, HDL-C and LDL-C \[[@CR13], [@CR15]--[@CR17]\]. ANGPTL8 or betatrophin- as called by Yi et al. has been suggested to increase beta-cell proliferation and beta-cell mass in insulin resistance mouse model \[[@CR18]\]. However, recent data challenged the findings of Yi et al. and it was shown that ANGPTL8 does not play a role in beta-cell proliferation under insulin resistance conditions \[[@CR19], [@CR20]\].

We have recently showed that ANGPTL8 is increased in T2D and was associated with increased C-peptide level in non-diabetic subjects \[[@CR21], [@CR22]\]. However, the role of ANGPTL8 in metabolic syndrome as well as its association with inflammatory markers like HsCRP has not yet been well studied. As a result, we designed this population study to look at the association between HsCRP and ANGPTL8 and their relationship with MetS and its components.

Research design and methods {#Sec2}
===========================

Study participants and anthropometric and physical measurements and ethics, consent and permissions {#Sec3}
---------------------------------------------------------------------------------------------------

This study was performed on 1735 adult (\>18 years old) South Asians (Indians and Pakistanis) and Arabs living in Kuwait as previously described \[[@CR21]--[@CR23]\]. Briefly, the samples have been continuously collected randomly from multi-ethnic subjects living in Kuwait. Subjects younger than 18 and older than 65 or suffering from any kind of infection were excluded. The non-diabetic subjects were then selected as subjects without disease and not taking any medications. Subjects with cardiovascular diseases were excluded from the study. No treatment was received before sampling. The study conformed to the principles outlined in the Declaration of Helsinki and in accordance with the approved guidelines. The study was approved by the Ethical Review Committee at Dasman Diabetes Institute (DDI). An informed written consent was obtained from all the participants before their enrolment in the study.

Physical and anthropometric measurements included body weight, height, waist circumference (WC). These were measured as described previously \[[@CR21]--[@CR23]\]; height and weight were measured, with participants wearing light indoor clothing and barefooted, using calibrated portable electronic weighing scales and portable inflexible height measuring bars. WC was measured using constant tension tape at the end of a normal exhalation, with arms relaxed at the sides, at the highest point of the iliac crest and at the mid-axillary line. BMI was calculated using the standard BMI formula: body weight (in kilograms) divided by height (in meters squared).

Laboratory measurements {#Sec4}
-----------------------

Blood samples were obtained after fasting overnight for at least 10 h and analyzed for Fasting Blood Glucose (FBG), hemoglobin A1c (HbA1c), fasting insulin, and lipid profiles that included triglyceride (TG), Total cholesterol (TC), low density lipoprotein (LDL) and high density lipoprotein (HDL). Glucose and lipid profiles were measured on the Siemens Dimension RXL chemistry analyzer (Diamond Diagnostics, Holliston, MA). HbA1c was determined using the VariantTM device (BioRad, Hercules, CA) as described earlier \[[@CR21]--[@CR23]\].

Diabetes and MetS diagnosis and guidelines {#Sec5}
------------------------------------------

The current recommendations and updated guidelines for the definition, diagnosis and classification of T2D, published by the International Diabetes Federation (IDF), have been used. Diabetes was defined by fasting plasma glucose ≥ 7 mmol/l, under treatment, or self-reported of previously diagnosed T2D \[[@CR24]\]. Impaired fasting glucose (IFG) was defined by fasting blood glucose values ≥ 5.6 and \<7 mmol/L. The current recommendations and updated guidelines for the definition, diagnosis and classification of MetS, published by the International Diabetes Federation (IDF), were used. MetS was defined by abdominal obesity and at least two of the following: fasting blood glucose values ≥ 5.6 mmol/L, hypertension was defined as BP ≥ 130/85 mmHg, under treatment, or a self-report of previously diagnosed hypertension \[[@CR25]\] Hypertriglyceridemia as ≥ 1.7 mmol/L and low HDL cholesterol as \<1.03 mmol/L in men and \<1.29 mmol/L in women. BMI between 18.5 and 24.9 was considered normal, 25--29.9, overweight, and equal to or higher than 30, was considered obese. Cutoffs for central obesity were adopted from IDF; they were defined based on race and gender. In Arabs WC ≥ 94 cm in men and ≥80 cm in women was used, whereas for South Asians central obesity cutoffs were WC ≥ 90 cm for men and WC ≥ 80 cm for women.

ANGPTL8 and HsCRP ELISA level {#Sec6}
-----------------------------

To measure metabolic markers, blood was drawn into EDTA tubes. Plasma was obtained after centrifugation, aliquoted and then stored at −80 °C. ANGPTL8 concentration was determined using ELISA (Wuhan EIAAB Science, China) as previously described \[[@CR21], [@CR22]\]. Optimal dilution was found to be between 1:10--1:40 and a dilution of 1:25 was used. Inter-assay coefficients of variation were 1.2 to 3.8 % while the intra-assay coefficients of variation were 6.8 to 10.2 %. HsCRP secreted level was measured using ELISA kit (Biovendor, USA) and measured according to manufacturer's protocol as previously described \[[@CR23]\].

Statistical analysis {#Sec7}
--------------------

Normality tests were run to assess data distribution. Comparisons between subjects with MetS and without MetS were made by Student's t test or Wilcoxon test for non-parametric analyses in variables with non-normal distribution. To assess the difference in categorical variables between subjects with and without MetS, a Chi Squared test was used. Spearman's correlation coefficients were estimated to determine associations between ANGPTL8, HsCRP and anthropometric measurements and biochemical variables. Subjects were classified into tertiles based on their circulating betatrophin levels in the overall population. ANGPTL8 tertile values are T1 ≤ 689.52.4 pg/mL, T2 689.52 ≤ 1302.63 pg/mL, T3 \> 1302.63 pg/mL. Tertile values of HsCRP are expressed as T1 (\<1.39), T2 (1.39--4.07), and T3 (\>4.07).

A multivariable logistic regression analysis was performed to estimate odds ratios (ORs) adjusted for covariates and to assess the predictive effect of betatrophin on risk for T2D. All data are reported as Mean ± standard deviation (SD) and range, unless stated otherwise. Research Electronic Data Capture (REDCap) was used for data collections and data management. All statistical assessments were two-sided and considered to be significant when *Pvalue* \<0.05. All analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC).

Results {#Sec8}
=======

Population characteristics are outlined in Table [1](#Tab1){ref-type="table"}. Our population was made of 1735 subjects, 724 of which were non-MetS and 1011 were MetS subjects. The average age of participants was 41.1 ± 10.6 for non-MetS subjects and 49.0 ± 10.9 for subjects with MetS. Subjects with MetS had a significantly higher BMI, waist/hip ratio, systolic and diastolic blood pressure, FBG, HBA1c, insulin, HOMA-IR, TG, TC, HDL, and LDL (p \< 0.05). ANGPTL8 showed close to twofold increase in subjects with MetS relative to non-MetS subjects 1140.6 (171.9--11736.1) pg/mL vs. 710.5 (59.5--11597.2) pg/mL respectively (P value \<0.0001) Table [1](#Tab1){ref-type="table"}. HsCRP level was 1.79 (0.01--31.00) μg/mL in non-MetS subjects vs. 2.94 in MetS subjects (0.01--31.00) μg/mL (P value \<0.0001) Table [1](#Tab1){ref-type="table"}.Table 1Clinical and biochemical profile for study subjectsVariableControl N = 724MetS N = 1011*P* valueAge (years)41.1 ± 10.649.0 ± 10.9\<0.0001Height (m)1.64 ± 0.091.65 ± 0.090.0723Weight (kg)74.4 ± 16.384.9 ± 17.1\<0.0001BMI (kg/m^2^)27.6 ± 5.331.3 ± 6.02\<0.0001Waist (cm)91.6 ± 12.7101.8 ± 12.4\<0.0001Hip (cm)102.3 ± 11.5108.8 ± 12.3\<0.0001Wc/hip ratio0.90 ± 0.080.94 ± 0.08\<0.0001Systolic (mmHg)123.7 ± 17.4137.7 ± 18.7\<0.0001Diastolic (mmHg)75.6 ± 10.682.6 ± 11.8\<0.0001FBG (mmol/L)5.39 ± 1.927.05 ± 2.9\<0.0001Hba1c (%)5.71 ± 1.156.85 ± 1.9\<0.0001Insulin μU/mL8.31 ± 13.613.56 ± 18.3\<0.0001HOMAIR2.13 ± 5.704.52 ± 2.70\<0.0001TC (mmol/L)5.05 ± 1.035.14 ± 1.120.0683TG (mmol/L)1.18 ± 0.611.86 ± 1.22\<0.0001HDL (mmol/L)1.27 ± 0.351.05 ± 0.27\<0.0001LDL (mmol/L)3.26 ± 0.933.28 ± 0.980.7189ANGPTL8 (pg/ml)710.5 (59.5--11597.2)1140.6 (171.9--11736.1)\<0.0001HsCRP (μg/mL)1.79 (0.01--31.00)2.94 (0.01--31.00)\<0.0001Results are reported as Mean ± SD except for non-normally distributed ANGPTL8 and HsCRP that are presented as median (range)

Comparing the Least Square Means (LSMeans) between non-MetS and MetS subjects showed significant increase in the level of ANGPTL8 in the MetS subjects as shown in Fig. [1](#Fig1){ref-type="fig"}a (*P* value = 0.032). Dividing the population according to the number of MetS components showed increased ANGPTL8 level as the number of MetS components increases Fig. [1](#Fig1){ref-type="fig"}b (P value \<0.0001).Fig. 1Circulating level of ANGPTL8 in subjects MetS. **a** Least square means of plasma level of ANGPTL8 in MetS vs non-MetS subjects. **b** Least square means of plasma level of ANGPTL8 according to the number of MetS components

Partial Spearman's correlation adjusted for gender and ethnicity showed that ANGPTL8 was positively correlated to HsCRP level (r = 0.15, *P* \< 0.001) Table [2](#Tab2){ref-type="table"}. ANGPTL8 also showed strong positive correlation to age (r = 0.59, *P* \< 0.001), BMI (r = 0.16, *P* \< 0.001), waist/hip ratio (r = 0.32, *P* \< 0.001), FBG (r = 0.43, *P* \< 0.001), HbA1c (r = 0.38, *P* \< 0.001), HOMA-IR (r = 0.33, *P* \< 0.001). Similarly using partial Spearman's analysis adjusting for gender and ethnicity HsCRP was positively associated with age, BMI, waist/hip ratio, FBG, HbA1c and HOMA-IR as shown in Table [2](#Tab2){ref-type="table"}.Table 2Partial spearman correlation coefficients of ANGPTL8 and CRP with various parameters adjusted for ethnicity and genderMarkersANGPTL8HsCRPrp valuerp valueAge0.59\<0.00010.090.0024BMI0.16\<0.00010.41\<0.0001WC/HIP ratio0.32\<0.00010.21\<0.0001FBG0.43\<0.00010.18\<0.0001Hba1C0.38\<0.00010.22\<0.0001Insulin0.19\<0.00010.33\<0.0001HOMAIR0.33\<0.00010.34\<0.0001HsCRP0.15\<0.00010.15\<0.0001

In order to understand the association between ANGPTL8 and HsCRP, the population was divided according to tertiles of HsCRP. Age and ethnicity adjusted estimates of ANGPTL8 means showed significant association between levels of ANGPTL8 and HsCRP among all subgroups. Overall, subjects in the highest tertiles of HsCRP had the highest ANGPTL8 levels Fig. [2](#Fig2){ref-type="fig"}a. Dividing the population according to MetS, both subjects in the MetS and non-MetS groups showed a similar trend where subjects in the highest tertile of HsCRP had the highest level of ANGPTL8 Fig. [2](#Fig2){ref-type="fig"}b, c.Fig. 2Association between ANGPTL8 and HsCRP according to MetS. **a** least square means of circulating level of ANGPTL8 according to HsCRP tertiles in all the subjects. **b** ANGPTL8 level in non-MetS subjects according to HsCRP tertiles. **c** ANGPTL8 level in MetS subjects according to HsCRP tertiles. Tertile values of HsCRP are expressed as T1 (\<1.39 μg/mL), T2 (1.39--4.07 μg/mL), and T3 (\>4.07 μg/mL)

In order to understand the effect of obesity on the association between the ANGPTL8 and HsCRP, the population was divided according to BMI into non-obese and obese subjects. BMI between 18.5 and 29.9 was considered non-obese, while BMI equal to or higher than 30 was considered obese. Weak association was observed between ANGPTL8 and HsCRP in the non-obese (*p* value = 0.0524) Fig. [3](#Fig3){ref-type="fig"}a. On the other hand, in the obese group, a significant association was observed and subjects in the highest tertiles of HsCRP had higher levels of ANGPTL8 (*p* value = \<0.0003) Fig. [3](#Fig3){ref-type="fig"}b.Fig. 3Association between ANGPTL8 and HsCRP according to obesity. **a** least square means of circulating level of ANGPTL8 according to HsCRP tertiles in non-obese subjects. **b** ANGPTL8 level in obese subjects according to HsCRP tertiles. Tertile values of HsCRP are expressed as T1 (\<1.39 μg/mL), T2 (1.39--4.07 μg/mL), and T3 (\>4.07 μg/mL). BMI between 18.5--29.9 was considered non-obese while BMI equal to or higher than 30, was considered obese

Multiple logistic regression analysis of ANGPTL8 and HsCRP showed that in the unadjusted model, subjects in the highest tertile of ANGPTL8 were more likely to have MetS (OR = 4.4, 95 % CI = 3.4--5.7) Table [3](#Tab3){ref-type="table"}. After adjustment for age, gender and ethnicity in Model-2, subjects in the highest tertile of ANGPTL8 had higher odds of having MetS (OR = 2.8, 95 % CI = 2.0--3.9). Further adjustment for HsCRP in Model-3 did not affect the association and subjects in the highest tertile still had higher odds of having MetS (OR = 2.4, 95 % CI = 1.6--3.6) (*P* trend \<0.0001). Multiple logistic regression analysis for HsCRP showed that in the unadjusted model, subjects in the highest tertile of HsCRP were more likely to have MetS (OR = 2.4, 95 % CI = 1.8--3.1) Table [3](#Tab3){ref-type="table"}. Further adjustment for age, gender and ethnicity in Model-2 and HsCRP in Model-3 did not affect the association and subjects in the highest tertile in model-3 still had higher odds of having MetS (OR = 2.3, 95 % CI = 1.6--3.1) (*P* trend \<0.0001) Table [3](#Tab3){ref-type="table"}.Table 3OR (95 % CI) by multiple logistic regression models for metabolic syndrome in relation to ANGPTL8 and HsCRPModelsT1T295 % CIT395 % CIP trendANGPTL8 Model 112.3(1.8--2.8)4.4(3.4--5.7)\<0.0001 Model 211.7(1.3--2.2)2.8(2.0--3.9)\<0.0001 Model 311.7(1.2--2.3)2.4(1.6--3.6)\<0.0001HsCRP Model 112.0(1.5--2.7)2.4(1.8--3.1)\<0.0001 Model 211.8(1.3--2.5)2.5(1.8--3.4)\<0.0001 Model 311.8(1.3--2.4)2.3(1.6--3.1)\<0.0001*Model 1* unadjusted; *Model 2* adjusted for age, gender and ethnicity; *Model 3* adjusted for ANGPTL8 + CRP + Model 2. Tertile values of HsCRP are expressed as T1 (\<1.39 μg/mL), T2 (1.39--4.07 μg/mL), and T3 (\>4.07 μg/mL). Tertile values of ANGPTL8 are T1 (\<689.52 pg/ml), T2 (689.52--1302.63 pg/ml), and T3 (\>1302.63 pg/ml)

Discussion {#Sec9}
==========

In this study we showed that ANGPTL8 circulation level was higher in subject with MetS as well as subjects with increasing number of MetS components such as insulin resistance and central obesity. ANGPTL8 showed significant association with HsCRP where both showed significant positive association with BMI, TG, LDL, HOMA-IR and FBG. Age and ethnicity adjusted estimates of ANGPTL8 were increased in concordance with HsCRP level in subjects with MetS or without as well as across different BMI groups. Finally, higher ANGPTL8 levels were associated with 2.4-fold increase in the odds of having MetS. Higher HsCRP levels on the other hand were associated with a 2.3-fold increase in the odds of having MetS. Taken together, our data clearly indicate that increased ANGPTL8 level is associated with higher level of HsCRP and incidence of MetS in our population.

ANGPTL protein family members have been shown to play a major role in obesity and metabolic diseases \[[@CR26]--[@CR29]\]. ANGPTL3 and 4 have been heavily involved in lipid metabolism through their regulation of lipoprotein lipase (LPL) activity \[[@CR26]\]. ANGPTL8 has been recently recognized as another member of this family that plays a role in lipid metabolism and insulin signalling \[[@CR14], [@CR15], [@CR17], [@CR21], [@CR22], [@CR30]\]. It has been shown to regulate LPL activity through its interaction with ANGPTL3 \[[@CR15]\]. It has also been found that an arginine (R) to tryptophan (W) R59W sequence variant in the ANGPTL8 gene has been associated with lower LDL-C and HDL-C in some ethnicities \[[@CR15]\]. Its overexpression leads to increased TG in serum while its knockout has led to increased LPL activity and reduced fatty acid uptake by adipose tissues \[[@CR30]\]. It has also been shown to play a role in insulin signalling and has been initially suggested to increase beta-cell proliferation \[[@CR13]\]. However, recent studies found that ANGPTL8 had no effect on beta cell growth in mice, thus raising questions on how ANGPTL8 improves glucose tolerance \[[@CR19], [@CR20]\]. We and others have recently showed that ANGPTL8 level was increased in T2D \[[@CR21], [@CR31]--[@CR33]\] and its level associated with FBG and insulin resistance in a large human cohort \[[@CR21]\]. We also showed that it was associated with C-peptide production in non-diabetic subjects \[[@CR22]\]. In this study we further show that ANGPTL8 is increased in MetS and is associated with HsCRP. Our current data is in line with what has been reported about the increased ANGPTL8 level in obesity and T2D \[[@CR21], [@CR31]--[@CR34]\]. Other studies showed that ANGPTL8 was reduced in T2D \[[@CR35], [@CR36]\]. MetS is recognized as a cluster of metabolic risk factors including central obesity and insulin resistance \[[@CR23], [@CR37]--[@CR39]\]. Based on its involvement in two key pathways (lipid metabolism and insulin resistance), we hypothesized that the increased ANGPTL8 level caused by insulin resistance in MetS subjects will lead to an increased release of TG into plasma. This may be done through its ability to regulate the cleavage of active ANGPTL3 that leads to inhibition of LPL enzyme activity \[[@CR15]\]. Cleavage of ANGPTL3 causes the release of its N-terminal domain that can act as a potent inhibitor of LPL activity \[[@CR15]\]. Even though this might be a plausible analysis, a follow up study will be necessary to establish causality highlighting one of the limitations of the current study due to its cross-sectional nature. On the other hand, one of the strengths of this study is the large sample size used as well as the population being studied, which has not been well studied yet and is being recognized as a high risk population particularly the South Asians. It important to note that the EIAAB ELISA used in this study recognizes ANGPTL8 at its N-terminus and measures the full length form. The C-terminal form of ANGPTL8 is measured using Phoenix Pharmaceuticals ELISA kit that reacts with C-terminus and measures truncated ANGPTL8 \[[@CR40], [@CR41]\]. We have recently showed that both forms show a similar trend in obesity and their level was reduced after exercise, however, only full length ANGPTL8 showed association with FBG \[[@CR40]\].

HsCRP has been shown to closely associate with MetS and acts as a marker for low grade systemic inflammation \[[@CR38]\]. Its addition to MetS definition has been suggested to increase its predictive power of CVD and T2D \[[@CR9]--[@CR12]\]. To gain better understanding on the function of ANGPTL8 in MetS we looked at its association with HsCRP as a marker of inflammation. This is because it has been suggested that the disease progression in subjects with MetS towards T2D is accompanied by increased inflammation \[[@CR42]\]. Our data shows positive correlation between ANGPTL8 and HsCRP suggesting that the inflammatory process might be connected to the increase in ANGPTL8 in humans that could result in aggravated dyslipidemia. Similarly, ANGPTL3 and 4 have previously showed positive association with MetS \[[@CR43]\] and ANGPTL4 showed positive association with CRP \[[@CR42]\]. The close association between the ANGPTL8 and HsCRP shows that ANGPTL8 may be used in the future as a predictor of MetS and possibly CVD in combination with HsCRP.

In conclusion, our data shows that circulating ANGPTL8 level is increased in subjects with MetS or some of its components and this increase coincide with increase in the HsCRP level where both proteins can act as independent predictors of MetS. This data highlights the potential role of ANGPTL8 in MetS and the potential usage of this molecule as a predictive biomarker for MetS and CVD in the future.
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